Relationship Between Cathepsin D, Urokinase, and Plasminogen Activator Inhibitors in Malignant Vs Benign Breast Tumours

Overview

Journal Br J Cancer

Specialty Oncology

Date 1991 Nov 1

PMID 1931618

Citations 8

Authors

D Foucre

C Bouchet

K Hacene

N POURREAU-SCHNEIDER

A Gentile

P M Martin

A DESPLACES

J Oglobine

Affiliations

Soon will be listed here.

Abstract

The concentrations of cathepsin D (Cath D), urokinase (uPA) and two plasminogen activator inhibitors (PAI-1 and PAI-2) were analysed in the cytosols of 130 human mammary tumours (43 benign tumours and 87 primary and unilateral breast carcinomas). uPA, PAI-1 and PAI-2 levels were measured by antigenic immunoassays and Cath D by immunoradiometric assay. The median levels of the four parameters were significantly higher in the malignant tumours than in the benign ones. Cath D and uPA increases were 4-fold and 5-fold respectively. PAI-1 and PAI-2 increases were much more important, 74-fold and 29-fold respectively. In malignant tumours, median levels of Cath D and uPA did not vary according to classical prognostic factors (histologic grade, presence or absence of axillary lymph nodes, steroid receptors, UICC stage, tumour size, age, and menopausal status). However, PAI-1 decreased in ER+ and PR+ tumours and PAI-2 increased in menopausal women's tumours. When Cath D, uPA, PAI-1 and PAI-2 levels in malignant tumours were compared, positive correlations were found for all combinations. The implication of plasminogen activator inhibitors in the phenomenon was surprising and merits further investigation using tools other than global antigen measurements in tumours.

Citing Articles

Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.

Jahkola T, Toivonen T, von Smitten K, Virtanen I, Wasenius V, Blomqvist C Br J Cancer. 1999; 80(1-2):167-74.

PMID: 10389993 PMC: 2363020. DOI: 10.1038/sj.bjc.6690336.

Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.

Knoop A, Andreasen P, Andersen J, Hansen S, Laenkholm A, Simonsen A Br J Cancer. 1998; 77(6):932-40.

PMID: 9528837 PMC: 2150087. DOI: 10.1038/bjc.1998.154.

Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.

Solomayer E, Diel I, Wallwiener D, Bode S, Meyberg G, Sillem M Br J Cancer. 1997; 76(6):812-8.

PMID: 9310251 PMC: 2228039. DOI: 10.1038/bjc.1997.467.

Plasminogen activator inhibitor type 2 in breast cancer.

Duggan C, Kennedy S, Kramer M, Barnes C, Elvin P, McDermott E Br J Cancer. 1997; 76(5):622-7.

PMID: 9303361 PMC: 2228003. DOI: 10.1038/bjc.1997.435.

Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods.

Gohring U, Scharl A, Thelen U, Ahr A, Crombach G, Titius B J Clin Pathol. 1996; 49(1):57-64.

PMID: 8666688 PMC: 1023159. DOI: 10.1136/jcp.49.1.57.

References

Mira-y-Lopez R, Osborne M, DePalo A, OSSOWSKI L . Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy. Int J Cancer. 1991; 47(6):827-32. DOI: 10.1002/ijc.2910470606. View

Stetler-Stevenson W . Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990; 9(4):289-303. DOI: 10.1007/BF00049520. View

McDonnell S, Matrisian L . Stromelysin in tumor progression and metastasis. Cancer Metastasis Rev. 1990; 9(4):305-19. DOI: 10.1007/BF00049521. View

ROCHEFORT H, Capony F, Garcia M . Cathepsin D: a protease involved in breast cancer metastasis. Cancer Metastasis Rev. 1990; 9(4):321-31. DOI: 10.1007/BF00049522. View

Sloane B, Moin K, Krepela E, Rozhin J . Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. Cancer Metastasis Rev. 1990; 9(4):333-52. DOI: 10.1007/BF00049523. View

Testa J, Quigley J . The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev. 1990; 9(4):353-67. DOI: 10.1007/BF00049524. View

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

Paranjpe M, Engel L, Young N, Liotta L . Activation of human breast carcinoma collagenase through plasminogen activator. Life Sci. 1980; 26(15):1223-31. DOI: 10.1016/0024-3205(80)90067-3. View

Bernik M, Wijngaards G, Rijken D . Production by human tissues in culture of immunologically distinct, multiple molecular weight forms of plasminogen activators. Ann N Y Acad Sci. 1981; 370:592-608. DOI: 10.1111/j.1749-6632.1981.tb29766.x. View

10.

Naito S, Kinjo M, Nanno S, Kohga S, Oka K, Tanaka K . Fibrinolysis-inhibitory activity of cultured human cancer cell lines. Gan. 1981; 72(1):1-7. View

11.

Liotta L, Goldfarb R, Brundage R, Siegal G, Terranova V, Garbisa S . Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res. 1981; 41(11 Pt 1):4629-36. View

12.

OGrady R, Upfold L, Stephens R . Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator. Int J Cancer. 1981; 28(4):509-15. DOI: 10.1002/ijc.2910280418. View

13.

Benjamin L, McGarry R, Hart D . Effect of retinoic acid on human neuroblastoma: correlation between morphological differentiation and changes in plasminogen activator and inhibitor activity. Cancer Chemother Pharmacol. 1989; 25(1):25-31. DOI: 10.1007/BF00694334. View

14.

McKeehan W, Sakagami Y, Hoshi H, McKeehan K . Two apparent human endothelial cell growth factors from human hepatoma cells are tumor-associated proteinase inhibitors. J Biol Chem. 1986; 261(12):5378-83. View

15.

Garcia M, Pages A, Richer G, Domergue J, Pages A, Cavalie G . Distribution of the Mr 52,000 estrogen-regulated protein in benign breast diseases and other tissues by immunohistochemistry. Cancer Res. 1986; 46(7):3734-8. View

16.

Duffy M, OGrady P, Simon J, Rose M, Lijnen H . Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors. J Natl Cancer Inst. 1986; 77(3):621-3. DOI: 10.1093/jnci/77.3.621. View

17.

Cajot J, Kruithof E, Schleuning W, Sordat B, Bachmann F . Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer. 1986; 38(5):719-27. DOI: 10.1002/ijc.2910380516. View

18.

Mignatti P, Robbins E, Rifkin D . Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell. 1986; 47(4):487-98. DOI: 10.1016/0092-8674(86)90613-6. View

19.

Gloor S, Odink K, Guenther J, Nick H, Monard D . A glia-derived neurite promoting factor with protease inhibitory activity belongs to the protease nexins. Cell. 1986; 47(5):687-93. DOI: 10.1016/0092-8674(86)90511-8. View

20.

Kruithof E, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H . Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood. 1987; 69(2):460-6. View